Business Context and Reporting Period
Company: Bovie Medical Corporation (Note: Input metadata referenced "Apyx Medical Corp," but the filing text identifies the registrant as Bovie Medical Corporation).
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2010.
Business Overview: Bovie Medical Corporation manufactures and markets electrosurgical devices, including generators, accessories, cauteries, and medical lighting. The company operates primarily in the United States and internationally through distributors. During the second quarter of 2010, the company consolidated its Canadian facility operations into its Clearwater, Florida facility.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Sales (Revenue) | $11,496,016 | $14,048,901 |
| Gross Profit | $4,601,171 | $6,300,956 |
| Gross Margin | 40.0% | 44.9% |
| Net Income (Loss) | $(170,010) | $605,885 |
| Operating Cash Flow | $(373,198) | $390,916 |
| Cash and Equivalents (End of Period) | $3,367,415 | $3,115,098 |
| Total Debt (Current + Long Term) | $3,807,500 | $4,875,000 |
| Working Capital | $12,708,250 | $10,741,070 |
Note: Total Debt includes current portion of mortgage note ($135,000), long-term mortgage note ($3,672,500), and current portion of amounts due to Lican ($50,000). The line of credit balance was $0 at June 30, 2010, compared to $1,000,000 at December 31, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 18.2% ($2.55 million) for the six months ended June 30, 2010, compared to the prior year. This was driven primarily by a 24.7% drop in electrosurgical product sales, specifically a significant reduction in ablator sales, partially offset by increased generator and cautery sales.
- Profitability Shift: The company reported a net loss of $170,010 for the six-month period, a reversal from a net income of $605,885 in the same period in 2009. This was largely due to lower gross profit and increased operating expenses.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 8.9% year-over-year. This increase included approximately $76,000 in one-time write-offs related to the consolidation of Canadian operations and increased costs for regulatory compliance and marketing.
- Non-Operating Gain: A significant non-cash gain of $617,165 was recorded from the change in fair value of warrant liabilities issued during a private placement in April 2010. Without this gain, the operating loss would have been significantly larger.
- Capital Structure: The company completed a private placement in April 2010, raising approximately $2.8 million in net proceeds. This improved liquidity and allowed the company to pay down its line of credit to zero.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management believes current cash on hand ($3.4 million) and anticipated cash flows will be sufficient to meet operating commitments for the next year. The company has secured additional borrowing capacity ($4.0 million available on an $8 million line of credit and $1 million on an equipment line).
- Unusual Items:
- Canadian Consolidation: Costs of approximately $175,000 were incurred to consolidate the Windsor, Canada facility into Florida, including a $67,000 impairment of intangible assets related to the workforce and $60,000 in leasehold write-offs.
- Warrant Liability: Warrants issued in the April 2010 private placement are classified as liabilities and revalued quarterly. The $617,165 gain in the current period was due to a decline in the company's share price post-issuance.
- Risks and Contingencies:
- Patent Litigation: On June 10, 2010, Salient Surgical Technologies and Medtronic filed a lawsuit alleging infringement of a patent regarding Bovie's SEER fluid-assisted electrosurgical devices. Plaintiffs seek a permanent injunction and unspecified damages. Management intends to defend vigorously.
- Related Party Litigation: On July 9, 2010 (subsequent to period end), the company filed a complaint against former director Steven Livneh regarding breach of contract and fiduciary duty related to the Seal-N-Cut product acquisition. Livneh was removed from the board on July 16, 2010.
- Customer Concentration: The ten largest customers accounted for 67% of net revenues for the six months ended June 30, 2010.
Investor Verification Checklist
- Verify the status and potential financial impact of the patent infringement lawsuit filed by Medtronic/Salient Surgical Technologies regarding the SEER device.
- Confirm the sustainability of the revenue decline in the electrosurgical disposable product line and the success of new product introductions (e.g., vessel sealing technology).
- Review the valuation assumptions used for the warrant liability, as fluctuations in stock price will continue to create volatility in reported earnings.
- Monitor the resolution of the legal dispute with former director Steven Livneh regarding the Seal-N-Cut intellectual property.
- Assess the company's ability to maintain compliance with debt covenants (debt-to-tangible net worth, debt-to-EBITDA) given the recent operating loss.